Latest news with #EnalaprilMaleateTablets
Business Standard
21-05-2025
- Business
- Business Standard
Stock Alert: Dixon Tech, Torrent Pharma, United Spirits, Aster DM Healthcare, J Kumar Infraprojects
Securities in F&O Ban: RBL Bank and Manappuram Finance shares are banned from F&O Trading on 21 May 2025. Upcoming Results: IndusInd Bank, Oil & Natural Gas Corporation (ONGC), Astral, Colgate Palmolive (India), H.G. Infra Engineering, InterGlobe Aviation, Ircon International, Mankind Pharma, National Aluminium Co, NTPC Green Energy, Oil India, Power Finance Corp, Rail Vikas Nigam, Trident, VRL Logistics will declare their results later today. Stocks to Watch: Dixon Technologies (India)s consolidated net profit surged 321.2% to Rs 400.82 crore on 121% jump in revenue from operations to Rs 10,292.54 crore in Q4 FY25 over Q4 FY24. Torrent Pharmaceuticals reported 10.9% jump in consolidated net profit to Rs 498 crore on 7.9% increase in revenue from operations to Rs 2,909 crore in Q4 FY25 over Q4 FY24. United Spirits consolidated net profit jumped 74.7% to Rs 421 crore on 8.9% increase in net sales (excluding excise duty) to Rs 3,031 crore in Q4 March 2025 over Q4 March 2024. Gland Pharmas consolidated net profit declined 3.1% to Rs 186.54 crore in Q4 FY25, compared with Rs 192.42 crore in Q4 FY24. Revenue from operations fell 7.3% YoY to Rs 1,424.91 crore in Q4 FY25. Aster DM Healthcare reported consolidated net profit of Rs 79.02 crore in Q4 FY25 compared with net loss of Rs 24.03 crore in Q4 from operations increased 2.7% YoY to Rs 1,000.34 crore during the quarter ended 31st March 2025. J kumar Infraprojects consolidated net profit rose 12.1% to Rs 114.20 crore on 14.6% jump in revenue from operations to Rs 1,632.74 crore in Q4 FY25 over Q4 FY24. Senores Pharmaceuticals (SPL)s US subsidiary, Senores Pharmaceuticals US has entered into an agreement to acquire US FDA- approved ANDA for Enalapril Maleate Tablets from Wockhardt. Enalapril is used for treatment of hypertension, heart failure.
Business Upturn
20-05-2025
- Business
- Business Upturn
Senores Pharmaceuticals acquires USFDA-approved ANDA for Enalapril Maleate Tablets from Wockhardt
By Aman Shukla Published on May 20, 2025, 15:47 IST Senores Pharmaceuticals Limited (SPL), through its wholly-owned US subsidiary, Senores Pharmaceuticals, Inc. (SPI), has entered into an agreement to acquire the USFDA-approved Abbreviated New Drug Application (ANDA) for Enalapril Maleate Tablets in four strengths: 2.5 mg, 5 mg, 10 mg, and 20 mg. The ANDA is being acquired from Wockhardt Limited. Enalapril Maleate is a generic pharmaceutical product indicated for the treatment of hypertension, heart failure, and asymptomatic left ventricular dysfunction. It is a widely prescribed medication in cardiovascular therapy. According to IQVIA, the U.S. market size for Enalapril Tablets was approximately USD 28.60 million as of MAT December 2024. Data from Symphony, a specialty data aggregator, places the market size at around USD 109.24 million as of MAT March 2025. The variation in estimates is attributed to differing data methodologies and sources. The acquisition by SPL will be financed using proceeds from the company's recent Initial Public Offering (IPO), aligning with the intended use of funds outlined in the Red Herring Prospectus filed during the IPO process. About Senores Pharmaceuticals Limited Senores Pharmaceuticals Limited is a research-focused pharmaceutical company engaged in the development and manufacturing of a diverse portfolio of pharmaceutical products. The company, along with its subsidiaries, serves regulated and emerging markets including the United States and Canada, with a focus on various therapeutic segments and dosage forms. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
